Novocure Revenue and Competitors
Estimated Revenue & Valuation
- Novocure's estimated annual revenue is currently $545.8M per year.
- Novocure received $150.0M in venture funding in February 2018.
- Novocure's estimated revenue per employee is $322,559
- Novocure's total funding is $875M.
- Novocure's current valuation is $7.4B. (January 2022)
Employee Data
- Novocure has 1692 Employees.
- Novocure grew their employee count by 9% last year.
Novocure's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | VP, Business Development | Reveal Email/Phone |
4 | Head Engineering | Reveal Email/Phone |
5 | SVP, Enterprise Transformation and Global Revenue Operations | Reveal Email/Phone |
6 | Head Global Procurement | Reveal Email/Phone |
7 | VP IT Infrastructure and Cybersecurity | Reveal Email/Phone |
8 | Head Talent & Development | Reveal Email/Phone |
9 | VP, Head Government Affairs | Reveal Email/Phone |
10 | VP, Thoracic Business Unit | Reveal Email/Phone |
Novocure Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $545.8M | 1692 | 9% | $875M | N/A |
#2 | $29.1M | 116 | 5% | N/A | N/A |
What Is Novocure?
We are a commercial-stage oncology company developing a novel, proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers. We count on the contributions of our talented team members who are committed to improving the lives of cancer patients. Here at Novocure, cancer patients and their families are and have always been at the core of our mission. We expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. We seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. We offer employment opportunities in the U.S., Europe and Asia.
keywords:Biotechnology,Hardware,Healthcare,Medical Devices,Pharmaceuticals
$875M
Total Funding
1692
Number of Employees
$545.8M
Revenue (est)
9%
Employee Growth %
$7.4B
Valuation
N/A
Accelerator
Novocure News
NovoCure is headquartered on the coast opposite Seagen, in New Jersey. Thus far, the company has expanded into Tokyo, Israel, and Root,...
The medical equipment provider reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.15). NovoCure had a...
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and...
ST. HELIER, Jersey--(BUSINESS WIRE)--Feb 25, 2021-- Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2020, highlighting revenue growth and financial strength as well as the advancement of the company’s clinical and product development pro ...
Novocure, a commercial stage oncology company, entered into a term loan agreement with an investment fund managed by Pharmakon Advisors LP. The agreement provides Novocure with up to $100m of available borrowing capacity. Under the terms of the agreement, Pharmakon will provide $25m at closing ...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $331.6M | 1692 | 5% | N/A |
#2 | $343.7M | 1693 | N/A | N/A |
#3 | $640M | 1693 | 39% | N/A |
#4 | $3.5M | 1701 | -1% | N/A |
#5 | $333.8M | 1703 | 8% | N/A |
Novocure Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2015-01-09 | $100.0M | Undisclosed | Pharmakon Advisors LP | Article |
| 2018-02-08 | $150.0M | Undisclosed | BioPharma Credit PLC | Article |